Chagas Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Chagas Disease Market Outlook

Thelansis’s “Chagas Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chagas Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chagas Disease Overview

Chagas disease, also known as American trypanosomiasis, is a zoonotic illness caused by the parasite Trypanosoma cruzi. The disease is primarily transmitted by the reduviid bug, commonly called the kissing bug or triatomine bug. Transmission occurs through contact with the bug's contaminated feces or urine. The parasite enters the body through mucous membranes or open bite wounds. The infective trypomastigote form is most concentrated in the feces of infected reduviid bugs. Alternate routes of transmission include: - Vertical transmission from mother to fetus, resulting in congenital Chagas disease - Organ transplantation - Transfusion of blood and blood products Upon entering the body through a wound or mucous membrane, the infectious trypomastigote can be found in the bloodstream plasma. The amastigote stage of the parasite resides within pseudocysts located in muscle or nerve cells. The parasite targets the myocardium and myenteric plexus of the gastrointestinal tract, where it multiplies through binary fission. The disease progresses through three phases: acute, indeterminate, and chronic. During the acute phase, symptoms can manifest shortly after infection and persist for approximately two months. Chronic infections can endure for many years. It can be treated using medications like nifurtimox and benznidazole, which exhibit over 80% effectiveness during the acute phase. However, they have no impact on the amastigote stage. Management of the chronic phase relies on supportive therapy tailored to the affected organ system. Unfortunately, there is currently no vaccine available for this disease. Prevention methods involve education, improved housing conditions, vector control using bed nets, and screening of blood donations and children in regions where the disease is prevalent.

• In the Americas, Chagas disease has an annual incidence of around 30,000 new cases, resulting in approximately 12,000 deaths annually. Additionally, roughly 9,000 newborns are infected during gestation. It is estimated that about 70 million people in the Americas live in areas with potential exposure to the disease and are at risk of contracting it.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: